Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections. This syndrome affects mostly women (\~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and "brain fog", commonly described in POTS patients are also present in this novel condition, recently named post-COVID-19 tachycardia syndrome, POTS variant. Reduced Vagal activity and unresolved inflammation is post-COVID-19 POTS is hypothesized as the cause of Long COVID

Who May Be Eligible (Plain English)

Who May Qualify: - Prior RT-PCR-confirmed COVID-19 infection. - Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\>30 bpm) and chronic (\>3 months) pre-syncopal symptoms. Who Should NOT Join This Trial: - Heart Disease: Myocardial Infarction, angina, heart failure - History of stroke, or transient ischemic attack - Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries) - Uncontrolled hypertension defined as persistent blood pressure \>140/90. - Post-menopausal women. - Diabetes Mellitus Type 1 or Type 2. , - Impaired Hepatic function - Impaired renal function test (eGFR\<60 mL/min/1.73m2). - Ongoing substance abuse. - Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study. - History of seizures. - Chronic use of steroids, NSAIDs. - On biologics such as anti-IL6 (omalizumab) and anti-TNF-alpha drugs - Pregnancy or breastfeeding Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Prior RT-PCR-confirmed COVID-19 infection. * Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\>30 bpm) and chronic (\>3 months) pre-syncopal symptoms. Exclusion criteria: * Heart Disease: Myocardial Infarction, angina, heart failure * History of stroke, or transient ischemic attack * Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries) * Uncontrolled hypertension defined as persistent blood pressure \>140/90. * Post-menopausal women. * Diabetes Mellitus Type 1 or Type 2. , * Impaired Hepatic function * Impaired renal function test (eGFR\<60 mL/min/1.73m2). * Ongoing substance abuse. * Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study. * History of seizures. * Chronic use of steroids, NSAIDs. * On biologics such as anti-IL6 (omalizumab) and anti-TNF-alpha drugs * Pregnancy or breastfeeding

Treatments Being Tested

DIAGNOSTIC_TEST

Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls

Inflammatory and immune profile of post-COVID-19 POTS patients. Reduced PNS activity (vagal tone) in relation to persistent inflammation.

DIAGNOSTIC_TEST

Levels of inflammatory cytokine ( IL-6) in controls

Inflammatory and immune profile of healthy controls. Controls are the subjects who recovered from COVID-19 infection with no sequelae.

DIAGNOSTIC_TEST

Effect on inflammation after chronic PNS stimulation

Inflammatory biomarkers after restoring PNS function in post-COVID-19 POTS patients, by chronic transcutaneous vagus nerve stimulation (tVNS) in post COVID-19 POTS patients

Locations (1)

Vanderbilt University Medical Center
Nashville, Tennessee, United States